Evidence map›Paper›PMID 40190553›Full record

ArticleFrontiers in oncology2025

Surgical and clinical impacts of mixed reality-guided glioblastoma resection versus standard neuronavigation: improving tumor surgery.

Julien Haemmerli, Samuel Khatchatourov, Etienne Chaboudez, Leonard Roth, Abiram Sandralegar, Insa Janssen, Denis Migliorini, Karl Schaller, Philippe Bijlenga

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julien Haemmerli *Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Samuel Khatchatourov *Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Etienne ChaboudezDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Leonard RothCentre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Abiram SandralegarFaculty of Medicine, University of Geneva, Geneva, Switzerland.
Insa JanssenDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Denis MiglioriniDepartment of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Karl SchallerDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
Philippe BijlengaDivision of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastomas (GBM) are typically treated with surgery and radio-chemotherapy, with patient survival often depending on the extent of tumor resection. This study compares outcomes of GBM surgery using 5-ALA, intraoperative neuroelectrophysiology, and neuro-navigation, either in a standard setting (STD) or enhanced by mixed reality (MR) guidance. Methods: This retrospective study included GBM patients who underwent resection at Geneva University Hospitals between 2015 and mid-2022, excluding biopsies and partial debulking. Primary outcomes included postoperative residual tumor volume (RV) based on postoperative contrast uptake on the MRI, while secondary outcomes were gross total resection (GTR), extent of resection (EOR), new postoperative deficits, overall survival (OS), progression-free survival (PFS), and Karnofsky performance scores. Confounding factors such as intraoperative monitoring and use of fluorescence were analyzed. Results: Of 115 patients, 76 were in the STD group and 39 in the MR group, with comparable demographics. The MR group had significantly lower RV (median 0.01 cm³ vs. 0.34 cm³, p=0.008) and higher GTR rates (median 50% vs. 26.7%). EOR was also superior in the MR group (median 99.9% vs. 98.2%, p=0.002). New focal deficits occurred in 39% (STD) and 36% (MR) of cases (p=0.84). While median OS was not significantly different (475 vs. 375 days, p=0.63), median PFS was longer in the MR group (147 vs. 100 days, p=0.004). Conclusion: MR guidance improves the quality of tumor resection and enhances progression-free survival without increasing postoperative deficits, although it does not significantly impact overall survival.

Indexed as

glioblastomasGTRmixed realityoncologic neurosurgeryprogression-free survival

Identifiers

PMID40190553
PMCPMC11968386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.